Page 10«..9101112..2030..»

Category Archives: Global News Feed

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Posted: April 21, 2025 at 2:44 am

CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.

See more here:
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Posted in Global News Feed | Comments Off on XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Posted: April 21, 2025 at 2:44 am

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IXCHIQ® for persons aged ?18 years traveling to a country or territory where there is a chikungunya outbreak. Additionally, it may be considered for persons aged ?18 years traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time e.g., six months or more.

Read more:
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Posted in Global News Feed | Comments Off on Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Posted: April 21, 2025 at 2:44 am

CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets.

See the rest here:
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Posted in Global News Feed | Comments Off on Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Dipharma Awarded Bronze Medal by Ecovadis for Sustainability

Posted: April 21, 2025 at 2:44 am

Recognition Underscores Commitment to Sustainable Practices Recognition Underscores Commitment to Sustainable Practices

Read more here:
Dipharma Awarded Bronze Medal by Ecovadis for Sustainability

Posted in Global News Feed | Comments Off on Dipharma Awarded Bronze Medal by Ecovadis for Sustainability

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Posted: April 21, 2025 at 2:44 am

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Continued here:
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Posted in Global News Feed | Comments Off on Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Posted: April 21, 2025 at 2:44 am

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo

Original post:
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Posted in Global News Feed | Comments Off on Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Posted: April 21, 2025 at 2:44 am

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD® (aflibercept) Injection 8 mg across all approved indications.

Follow this link:
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Posted in Global News Feed | Comments Off on Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

23andMe Provides Update Regarding Court-Supervised Sale Process

Posted: April 21, 2025 at 2:44 am

SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today provided additional information on the protections in place for customer data in connection with the court-supervised sale of the Company’s assets. The process is being led by the Special Committee of the Company’s Board of Directors, which will evaluate potential acquisition bids, and supervised by the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court”), an independent third party who must review and approve any transaction.

Read the original post:
23andMe Provides Update Regarding Court-Supervised Sale Process

Posted in Global News Feed | Comments Off on 23andMe Provides Update Regarding Court-Supervised Sale Process

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Posted: April 21, 2025 at 2:44 am

Company announcement – No. 9 / 2025

See the rest here:
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Posted in Global News Feed | Comments Off on Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Boston Hemp Launches New Line of Premium THCa Concentrates

Posted: April 21, 2025 at 2:44 am

Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in compliant hemp-derived cannabis, today announced the launch of its new line of premium THCa concentrates, now available to consumers nationwide. The new lineup includes THCa dabs, THCa shatter, THCa diamonds, badder, and isolate powder—delivering a high-potency experience for both recreational and wellness-minded users.

More here:
Boston Hemp Launches New Line of Premium THCa Concentrates

Posted in Global News Feed | Comments Off on Boston Hemp Launches New Line of Premium THCa Concentrates

Page 10«..9101112..2030..»